AbbVie reports Q4 and full-year 2025 results

AbbVie Inc. filed a current report stating that it issued a press release with its financial results for the fourth quarter and full year ended December 31, 2025.

Rhea-AI Filing Summary

AbbVie Inc. filed a current report stating that it issued a press release with its financial results for the fourth quarter and full year ended December 31, 2025. The company released these results on February 4, 2026, and attached the full press release as Exhibit 99.1.

The filing is presented under the Results of Operations and Financial Condition section, indicating the update relates to AbbVie’s operating performance and overall financial health for 2025. Detailed figures and metrics are contained in the referenced press release rather than in this summary document.

Insights

Equity research analyst

AbbVie released Q4 and full-year 2025 results via an attached press release.

AbbVie Inc. disclosed that it issued a press release covering financial results for the fourth quarter and full year ended December 31, 2025. The report is furnished as Exhibit 99.1, so the core quantitative details are contained in that attachment.

The use of an Item 2.02 current report signals a standard earnings-related disclosure. Without the underlying figures, this event appears procedural, providing investors with formal access to AbbVie’s 2025 performance data through the referenced press release.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did AbbVie (ABBV) disclose in this Form 8-K filing?

AbbVie disclosed that it issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. The complete results are contained in the press release furnished as Exhibit 99.1 to the filing.

Which period do AbbVie’s reported results in this filing cover?

The results cover AbbVie’s financial performance for the fourth quarter and full year ended December 31, 2025. The filing specifies that the press release reports both quarterly and full-year figures for this period, giving a comprehensive view of 2025 performance.

When did AbbVie release its Q4 and full-year 2025 financial results?

AbbVie released its Q4 and full-year 2025 financial results on February 4, 2026. That date is identified as the date of the press release and the earliest event reported, aligning the disclosure timing with the furnished Exhibit 99.1.

Where can investors find AbbVie’s detailed Q4 and 2025 financial figures?

Investors can find AbbVie’s detailed Q4 and full-year 2025 financial figures in the press release attached as Exhibit 99.1. The current report states that this exhibit is incorporated by reference, making it the primary source for numerical results.

What exhibit numbers are included in AbbVie’s current report for these results?

The filing lists Exhibit 99.1 as the press release dated February 4, 2026, containing the financial results. It also references Exhibit 104, which is the cover page information formatted in Inline XBRL, included within Exhibit 101 for reporting purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 07:54 AM Learn about SEC filing dates

0001551152false00015511522026-02-042026-02-040001551152us-gaap:CommonStockMemberexch:XNYS2026-02-042026-02-040001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec1250SeniorNotesDue2031Memberexch:XNYS2026-02-042026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 _____________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2026

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35565

32-0375147

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

 _____________________________________________________

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 Par Value

ABBV

New York Stock Exchange

NYSE Texas

0.750% Senior Notes due 2027

ABBV27

New York Stock Exchange

2.125% Senior Notes due 2028

ABBV28

New York Stock Exchange

2.625% Senior Notes due 2028

ABBV28B

New York Stock Exchange

2.125% Senior Notes due 2029

ABBV29

New York Stock Exchange

1.250% Senior Notes due 2031

ABBV31

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  

Item 2.02.  Results of Operations and Financial Condition

On February 4, 2026, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.						Exhibit
99.1						Press Release dated February 4, 2026 (furnished pursuant to Item 2.02).
104						The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

									ABBVIE INC.
Date:			February 4, 2026			By:			/s/ Scott T. Reents
									Scott T. Reents
									Executive Vice President,
									Chief Financial Officer